# Augmenting the Quality and Duration of the Immune Response with a Novel TLR2 Agonist-Aluminum Combination Adjuvant

> **NIH NIH N43** · TEICHOS LABORATORIES, LLC · 2021 · $300,000

## Abstract

The goal of this project is to optimize a novel adjuvant formulation composed of alum and a TLR2 agonist to improve performance of a DTaP subunit vaccine.

## Key facts

- **NIH application ID:** 10499193
- **Project number:** 75N93021C00057-0-9999-1
- **Recipient organization:** TEICHOS LABORATORIES, LLC
- **Principal Investigator:** LARRY BLASZCZAK
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $300,000
- **Award type:** —
- **Project period:** 2021-09-30 → 2022-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10499193

## Citation

> US National Institutes of Health, RePORTER application 10499193, Augmenting the Quality and Duration of the Immune Response with a Novel TLR2 Agonist-Aluminum Combination Adjuvant (75N93021C00057-0-9999-1). Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/grant/nih/10499193. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*